HOME >> BIOLOGY >> NEWS
Progress toward a targeted therapy for a specific form of leukemia

Leuven, Belgium -- Leukemia, or cancer of the bone marrow, strikes some 700 Belgians each year. Scientists are still searching for the cause of many forms of leukemia, including T-cell acute lymphoblastic leukemia, or T-ALL. Now, VIB researchers connected to the Katholieke Universiteit Leuven have identified a new player in the development of some 10% of the T-ALL cases: MYB. The scientists have discovered that patients in this group have a duplication of the MYB gene, which increases MYB concentrations. Further research has indicated that MYB might well be an important target for therapies for this group of T-ALL patients.

T-cell acute lymphoblastic leukemia (T-ALL)

Our bodies white blood cells combat foreign intruders such as viruses and bacteria. However, in leukemia, the formation of white blood cells is disrupted. The cells in the bone marrow that should develop into white blood cells multiply out of control without fully maturing. These blood cells do not function properly and thus jeopardize the production of normal blood cells. Among other consequences, this makes patients more susceptible to infections. T-ALL is a certain form of leukemia in which immature T-cells (a specific type of blood cells) build up very rapidly. T-ALL is the most prevalent form of cancer in children under 14 years of age, striking children between the ages of 2 and 3 in particular. Today, with optimal treatment using chemotherapy, more than half of the children are cured.

Combined action of several players

The search for the mechanisms that cause T-ALL goes on ceaselessly. Discovering these mechanisms will enable the development of targeted therapies, which are preferred over chemotherapy. Scientists know that T-ALL arises only when defects occur in several genes simultaneously. So it is not only important to identify the genes that underlie T-ALL, but also to discover which combinations trigger the disease. This is an important step in
'"/>

Contact: Ann Van Gysel
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
15-Apr-2007


Page: 1 2 3

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress against sarcoma
3. Progress toward artificial photosynthesis?
4. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
5. Progress in battle against life-threatening acute allergy
6. Progress report on Homogeneous Assay project
7. Progress being made in exploring potential use of stem cells to treat heart disease
8. Media Invite: Dinner to award prize for Progress in Cancer Research
9. Progress needed on global regime for access to genetic resources and benefit-sharing
10. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced
11. Progress toward a new remedy for chronic urinary tract infections?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2019)... ... , ... In the development of biosimilars, the broad definition of the similarity ... this uncertainty, several manufacturers have been successful and numerous follow-on biologics are approved in ... learn how analytical similarity is achieved in biosimilars based on recently approved products in ...
(Date:3/27/2019)... ... March 26, 2019 , ... Evan Holden , a ... LLP , was a panelist at the National Academy of Sciences (NAS) Roundtable on ... Holden, a member of the firm’s award-winning Pharmaceutical, Medical Device & Health Care ...
(Date:3/25/2019)... ... March 25, 2019 , ... Researchers have found ... technology since it came into use by the scientific community. Keck Graduate Institute ... the first to combine the power of CRISPR’s nucleic acid targeting with the ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... April 10, 2019 , ... After more than three months of renovation, Lajollacooks4u ... equipped with updated appliances and modern lighting and fixtures, and will provide additional workspace ... “We’ve seen tremendous growth in the demand for our team-building events and cooking classes ...
(Date:4/8/2019)... ... , ... US Capital Global Securities , an affiliate of US Capital ... privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of drugs ... dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, ...
(Date:3/27/2019)... POWAY, Calif. (PRWEB) , ... March 26, 2019 , ... ... autologous adipose-derived stem cell services to veterinarians across the United States and Canada since ... well as bone and soft tissue injuries in the dog, cat, and horse. ...
(Date:3/19/2019)... , ... March 19, 2019 , ... The AACR annual ... great opportunity to see the most cutting-edge cancer research. The Visikol team will be ... 3D cell culture assays as well as their digital pathology services . ...
Breaking Biology Technology:
Cached News: